Loading...
Loading...
AMGN| Name | Value |
|---|---|
| Revenues | 7,447.0M |
| Cost of Revenue | 3,200.0M |
| Gross Profit | 4,247.0M |
| Operating Expense | 3,256.0M |
| Operating I/L | 991.0M |
| Other Income/Expense | -1,059.0M |
| Interest Income | 0.0M |
| Pretax | -68.0M |
| Income Tax Expense | 45.0M |
| Net Income/Loss | -113.0M |
Amgen Inc. is a global biotechnology company that specializes in discovering, developing, manufacturing, and delivering human therapeutics. The company's products cover a wide range of medical areas including inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Its product portfolio includes Enbrel, Neulasta, Prolia, Xgeva, Otezla, Aranesp, KYPROLIS, Repatha, Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers and distributes its products through pharmaceutical wholesale distributors and direct-to-consumer channels.
